NCT00798889已完成不适用
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 314
- 试验地点
- 1
- 主要终点
- Duration of Treatment
研究概览
简要总结
The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prior SU011248 Protocol.
- •Eligible to continue SU011248 treatment.
排除标准
- •Uncontrolled CNS metastasis.
- •Unfit to receive SU011248.
研究组 & 干预措施
Sunitinib
Experimental
干预措施: Sunitinib (Drug)
结局指标
主要结局
Duration of Treatment
时间窗: Baseline up to Day 28 after last dose of study treatment
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.NeoplasmsNCT00443534Pfizer123
进行中（未招募）
1 期
A Rollover Study of CC-122Non-Hodgkin LymphomaNCT05688475Bristol-Myers Squibb12
已完成
2 期
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabMultiple MyelomaNCT02719613Bristol-Myers Squibb67
Approved For Marketing
不适用
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell CarcinomaCarcinoma, Renal CellNCT00130897Pfizer
进行中（未招募）
1 期
ong-term safety of IbrutinibMedDRA version: 21.1Level: PTClassification code 10043515Term: Throat cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10009944Term: Colon cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10042080Term: Stomach cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10029473Term: Nodular (follicular) lympEUCTR2016-004356-30-BEPharmacyclics Switzerland GmbH500